35 results about "Streptococcus bacteria" patented technology

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

A method for producing a fermented milk product (e.g. a yogurt) with a relatively high stable pH value at the end of the fermentation comprising inoculating milk with Streptococcus thermophilus (ST) Gal(+) bacteria.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

The application belongs to the technical field of microorganisms, and provides a Streptococcus salivarius subsp. thermophilus HX-ST36, which has a preservation number of CGMCC NO. 32955. The Streptococcus salivarius subsp. thermophilus provided by the application can ferment Astragalus membranaceus Bunge-Angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrhea model mouse, the fermentation product thereof can significantly inhibit the writhing response, and can realize the effects of relieving dysmenorrhea and tonifying blood by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the hemoglobin (HGB) content. The effect of the fermentation product in removing dampness is verified by improving the dampness signs of a crowd. The application further provides a probiotic preparation and a preparation method of a probiotic fermentation product. The preparation method of the probiotic preparation and the probiotic fermentation product is simple and can be produced on a large scale.

Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.

This invention discloses a synergistic anti-caries oral care composition and its application. The composition comprises: (a) a single-domain antibody targeting the Streptococcus mutans surface protein PAc; (b) a plant extract complex containing kudzu root extract and phellodendron bark extract; and (c) gallic acid liposomes. This invention also provides a toothpaste containing this composition and a method for its preparation. Experiments have shown that the single-domain antibody can specifically bind to and disturb the Streptococcus mutans biofilm, increasing cell membrane permeability and synergistically promoting the entry of plant extracts into the cell to exert a bactericidal effect, achieving a clearance rate of over 98% for mature biofilms. Through formulation and process optimization, this invention solves the stability problem of antibodies in toothpaste; the product retains more than 90% of its activity after two years of storage at 25°C. The composition and product provided by this invention have the advantages of highly efficient removal of mature biofilms, synergistic effect, safety with low damage, and excellent stability, and have broad application prospects in the field of oral care.

This invention discloses a multi-drug composition for the treatment of ankylosing spondylitis. For the first time, this invention addresses the etiology of streptococcus-related diseases by proposing a synergistic treatment strategy combining a classic tumor necrosis factor antagonist (such as etanercept) with a narrow-spectrum antibiotic (benzathine penicillin). This approach breaks through the traditional treatment strategy that targets only the inflammatory pathway, providing a novel entry point for AS treatment.

The application relates to the application of natural plant extracts in the field of oral health, and particularly discloses the application of an extract of Ilex hainanensis Merr in oral health care products. The Ilex hainanensis Merr dichloromethane extract is eluted by high-concentration ethanol through a macroporous resin, and is rich in dihydrochalcone active ingredients, has significant inhibitory activity on Porphyromonas gingivalis and Fusobacterium nucleatum, and has no inhibitory effect on Streptococcus mutans, can selectively inhibit periodontal pathogenic bacteria without destroying the oral microecological balance, and is suitable for preparing toothpaste, mouthwash, oral spray and other oral health care products.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

This invention belongs to the interdisciplinary field of natural product medicinal chemistry and oral medicine, specifically disclosing the application of uvangoletin in the preparation of anti-periodontalgia drugs. Uvangoletin is 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-1-propanone, with the molecular formula C. 16 H 16 O4, experiments confirmed that its MIC for Porphyromonas gingivalis was 16 μmol / L, MIC 50 The concentration is 10.28 μmol / L, the MIC for Fusobacterium nucleatum is 16 μmol / L and the MIC50 is 6.86 μmol / L. It has no inhibitory activity against Streptococcus mutans and has selective anti-periodontal pathogenic bacteria characteristics. It can be made into oral preparations such as gels, mouthwashes or toothpaste.

The application discloses an intestinal flora marker related to obstructive sleep apnea with obesity, a product and application thereof, and the intestinal flora marker combination is a marker combination composed of Streptococcus thermophilus, Faecalibacterium prausnitzii, Dorea longicatena and Bacteroides finegoldii. The application of a reagent for detecting the intestinal flora marker combination in preparation of a product for diagnosing obstructive sleep apnea with obesity is characterized in that the reagent comprises cetyltrimethylammonium bromide. The application provides a new idea and approach for diagnosis and treatment of obstructive sleep apnea with obesity.

The present application relates to the technical field of fermentation medium, more specifically, it relates to a high-density fermentation medium for streptococcus suis and preparation and application thereof.The medium comprises beef infusion powder 1-5 parts, tryptone 1-10 parts, pancreatic casein peptone 1-10 parts, soybean peptone 1-5 parts, dipotassium hydrogen phosphate 1-5 parts, sodium chloride 1-10 parts, yeast extract 1-10 parts and glucose 1-5 parts.

The present invention relates to a novel peptide comprising the amino acid sequence of SEQ ID NO: 1, and an antibacterial composition comprising same. The peptide of the present invention, which is an Enterococcus lactis-derived antibacterial peptide APP101, has specific antibacterial activity against periodontitis-causing bacteria including Porphyromonas gingivalis, Fusobacterium nucleatum, Enterococcus faecalis, Streptococcus parasanguinis, and Streptococcus salivarius, and has stability against proteases, pH, and salt concentrations. The antimicrobial composition of the present invention can be usefully employed for the prevention or treatment of periodontitis.

The present invention relates to the field of aquaculture, in particular to tilapia farming, and more particularly, the present invention relates to a novel bacterium of Streptococcus agalactiae serotype Ia (Sa Ia) which is much more pathogenic than the Sa Ia isolates known so far and which can break the protection provided by the existing Sa Ia vaccine. In particular, the present invention relates to a novel breaking Sa Ia bacterium which is defined by a number of unique characteristics and which is deposited at the CNCM in Paris. Furthermore, the present invention relates to preparations, compositions and vaccines of the novel Sa Ia bacterium, to diagnostic kits, and to the (medical) use and manufacturing process of the preparations, compositions and vaccines of the novel Sa Ia bacterium.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to an antibacterial small-molecule compound targeting bacterial phospholipid synthetase. The present application provides an antibacterial intervention strategy based on a novel mechanism of action, taking the key enzyme PlsY of bacterial specific membrane phospholipid synthesis as a target, and cracking the cross-resistance problem caused by the concentration of existing antibacterial drug targets. The lead compound T1 obtained by screening has strong inhibitory activity on PlsY, can effectively inhibit pathogenic bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, and has better selective toxicity because the human body has no PlsY homologous protein. The compound has a novel structure and can be optimized, and can be rationally designed through structure-activity relationship, and also has inhibitory effect on plant pathogenic bacteria. The present application opens up a new antibacterial pathway, provides differentiated candidate molecules and reserves for coping with multi-drug resistant infections, and has medical and agricultural potential, and has significant innovation and practicality.

This invention discloses the application of L-tryptophan in the preparation of anti-caries oral care products, belonging to the field of biomedical technology. Addressing the safety issues, oral microecological disruption, and susceptibility to drug resistance associated with existing anti-caries agents (such as fluoride and chlorhexidine), this invention proposes using L-tryptophan as the effective active ingredient in anti-caries agents. Utilizing the specific effects of L-tryptophan on *Streptococcus mutans*, it achieves the effects of inhibiting tooth decay, maintaining oral microecological balance, and reducing the risk of bacterial drug resistance. This specific effect, without affecting the survival of *Streptococcus mutans*, simultaneously inhibits the synthesis of water-insoluble extracellular polysaccharides, inhibits acid production and acid tolerance, and inhibits oxygen tolerance and interspecies competition. It is characterized by its clear efficacy and high safety.

This invention relates to the field of compound essential oils of traditional Chinese medicine, and particularly to a compound essential oil of traditional Chinese medicine for the adjuvant intervention against Streptococcus pneumoniae and its preparation method. The raw materials include the following by weight: 3-8 parts of patchouli essential oil; 2-6 parts of clove essential oil; 2-5 parts of costus root essential oil; 2-6 parts of nard essential oil; 3-7 parts of calamus essential oil; 1-4 parts of asarum essential oil; 3-8 parts of peppermint essential oil; 2-6 parts of artemisia essential oil; 3-7 parts of eupatorium essential oil; 45-80 parts of base oil; 2-5 parts of solubilizer; and 1-3 parts of penetration enhancer. This invention addresses the core issues of "respiratory inflammation, sputum accumulation, and decreased body defense" caused by Streptococcus pneumoniae. Through the scientific formulation of active molecules from nine kinds of Chinese herbal essential oils, a comprehensive synergistic system is formed, which has the functions of "antibacterial and antiviral, anti-inflammatory and lung-clearing, expectorant and cough-relieving, and enhanced defense." It features strong synergistic activity of active molecules, high specificity, high retention and utilization rate of active molecules, safe and convenient use, wide applicability, and simple preparation process.

The application discloses a traditional Chinese medicine composition of paris polyphylla and application of the traditional Chinese medicine composition in preparation of an oral cavity pathogenic bacterium activity inhibitor. The traditional Chinese medicine extract and extract of the application have the advantages of being natural, efficient, inexpensive, low in toxicity, easy to obtain and the like, and have obvious inhibiting effects on formation of oral cavity pathogenic bacterium Streptococcus mutans biofilm. The biofilm inhibition rate of the paris polyphylla alcohol extract is above 90%, the bacteriostatic rate of the Coptis deltoidea water extract is above 90%, and the bacteriostatic rate and the biofilm inhibition rate of the combination of the two are above 99%. The active ingredient acquisition method of the application is simple, safe and low in cost, and is convenient to popularize and use. The application further provides a natural medicine combination caries prevention method. The combination of drugs can not only enhance the treatment effect, but also serve as an effective prevention means to reduce drug resistance of oral cavity pathogenic bacteria.

The present disclosure relates to methods of treating triple negative breast cancer or non-muscle invasive bladder cancer in a subject comprising administering to the subject a composition comprising non-viable cells of Streptococcus pyogenes and an immune checkpoint inhibitor.

The application discloses a kind of instant cooking type prefabricated ya fish soup and its preparation method, mainly related to fish soup processing technical field.The preparation method of instant cooking type prefabricated ya fish soup includes the following steps, by weight part: (1) selecting fresh and live ya fish, after bloodletting, it is placed in ice water bath and is stationary, scale, gill, internal organs and abdominal cavity black film are removed, along the spine is split into two halves and main thorn is removed, fish meat surface is obliquely cut 3~5 depth 0.5cm's air groove, is soaked with 5~15 physiological saline and 15~25 streptococcal nisin mixed solution, drain water, select fresh mushroom, white radish, corn as auxiliary material, after washing, cut block is used;(2) the ya fish piece of drain is placed in sterile sealed box, evenly sprays composite enzymatic hydrolysis solution.The application is stewed by anhydrous, realizes high retention of umami, fish meat is more tender, deodorization is thorough and does not return fishy smell, soup body is stable and does not separate, and process is suitable for industrial production, and eating is convenient.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

This invention discloses a triple inactivated vaccine against porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae, and Streptococcus suis, and its preparation method, belonging to the field of veterinary biological products technology. The invention consists of an antigen and a vaccine adjuvant; the antigen is composed of PCV2 antigen, Mycoplasma hyopneumoniae antigen, and Streptococcus suis antigen; the PCV2 antigen is the PCV-2 d-cap protein obtained through genetic engineering; the Mycoplasma hyopneumoniae antigen is inactivated Mycoplasma hyopneumoniae (ES-2) bacterial suspension; the Streptococcus suis is inactivated SS2 and SS9 type Streptococcus suis bacterial suspension; the adjuvant is a novel aqueous adjuvant capable of enhancing cellular and humoral immunity. The triple inactivated vaccine against PCV2, Mycoplasma hyopneumoniae, and Streptococcus suis provided by this invention exhibits significant advantages in preventing these three swine diseases.

The application discloses a preparation method and application of a natural active ingredient compound nanogel agent for animals, and belongs to the technical field of veterinary drug preparations. The natural active ingredient compound nanogel agent disclosed by the application is composed of natural active ingredients, a gel matrix and additional agents, is reasonable in formula, simple in process, stable in property, convenient to use and safe and long-acting. The natural active ingredient compound nanogel agent contains two synergistically acting natural active ingredients, can inhibit the proliferation of endometritis pathogenic bacteria such as staphylococcus aureus and streptococcus, and reduce the expression of pro-inflammatory cytokines at an inflammation site; meanwhile, the natural active ingredient compound nanogel agent has a certain slow-release capacity, slowly releases natural active ingredient nanoparticles easy to be taken by cells, can realize long-time residence and high-efficiency absorption of drugs at a drug administration site, and thus can enhance the action time, reduce the drug administration frequency and improve the curative effect.

The present application relates to a kind of essential oil composition with the efficacy of improving immunity, belong to daily chemical technology field.The essential oil composition with the efficacy of improving immunity of the present application includes the following mass parts of components:Rowensha leaf essential oil 10-20 parts, eucalyptus essential oil 15-30 parts, green flower of guettarda speciosa essential oil 10-20 parts, guaiac essential oil 5-10 parts, cedar essential oil 5-20 parts.The essential oil composition with the efficacy of improving immunity of the present application can significantly reduce the secretion of TNF-alpha, and have certain inhibitory effect on streptococcus pneumoniae, haemophilus influenzae, in addition, also have certain antitussive efficacy, thereby verifying its efficacy of improving immunity, relieving respiratory discomfort.The composition of the present application can be used for preparing massage oil, aromatherapy spray, inhalant, cream, patch and other care products, with good application prospect.

The application provides a primer composition, a kit and application thereof for efficiently detecting common pathogenic bacteria of human, relates to the technical field of microorganism gene detection, and aims at solving the defects of low detection efficiency, poor specificity, low sensitivity of traditional PCR technology, and non-specific amplification of traditional LAMP detection technology. The application designs primers according to known sequences of six common pathogenic bacteria of human, i.e., Candida albicans, Chlamydia trachomatis, Escherichia coli, group B streptococcus, Mycoplasma hominis and Streptococcus pneumoniae, and provides a kit with a micro-fluidic chip as a carrier and application thereof, which are used for detecting common pathogenic bacteria of human, have high specificity and high sensitivity, reduce detection cost and detection time, and can realize on-site rapid detection of common pathogenic bacteria of human.

The application provides a kit for detecting common pathogenic bacteria of otitis media based on a multi-enzyme constant temperature rapid nucleic acid amplification technology, which comprises a first primer pair for detecting Streptococcus pneumoniae, a second primer pair for detecting Haemophilus influenzae, a third primer pair for detecting Moraxella catarrhalis, a fluorescent probe combination and a colloidal gold probe combination; the nucleotide sequences of the first primer pair are SEQ ID NO: 2 and SEQ ID NO: 4 respectively, the nucleotide sequences of the second primer pair are SEQ ID NO: 9 and SEQ ID NO: 10 respectively, and the nucleotide sequences of the third primer pair are SEQ ID NO: 13 and SEQ ID NO: 18 respectively. The application provides a triple multi-enzyme constant temperature rapid synchronous detection kit and a detection method, which have high sensitivity, high specificity and convenient operation, and meet the requirements of rapid diagnosis on the spot in a clinic.

The application discloses yoghourt and a preparation method thereof. The yoghourt comprises white granulated sugar, raw cow milk, apple fiber and streptococcus thermophilus. In the preparation process, the yoghourt is prepared through the ingredients and processes of material preparation, hydration, degassing, homogenization, sterilization, preheating, fermentation, material cooling, filling and the like. The yoghourt is a stirred-type fermented milk product with high viscosity. The yoghourt has high viscosity and strong accumulation feeling. The apple fiber can improve the viscosity and accumulation feeling of the yoghourt, and the viscosity, stability and texture characteristics, stability and aroma of the yoghourt are improved.

The present invention provides a composite biocontrol bacterial seed treatment agent containing Streptococcus thermophilus, a preparation method and an application, belonging to the technical field of biological pesticides. The seed treatment agent is a solid powder consisting of 80% to 90% effective active component and 10% to 20% auxiliary materials. The effective active component is an equal-proportion composite bacterial fermentation broth concentrate solidification product of Bacillus subtilis, Bacillus cereus, Bacillus thuringiensis and Streptococcus thermophilus. In the present invention, the fermentation concentrate of multiple bacterial strains is mixed with a carrier and spray- dried to obtain the composite bacterial fermentation broth concentrate solidification product; then the solidification product is mixed with the auxiliary materials to obtain the present invention.

The present invention relates to a Streptococcus zooepidemicus SMT013 strain having an increased ability to produce hyaluronic acid, a variant thereof, and a method for producing hyaluronic acid using same. The Streptococcus zooepidemicus SMT013 strain according to an aspect has an increased ability to produce hyaluronic acid, and thus can be used to produce hyaluronic acid. Also, provided are a medium composition for a microorganism producing hyaluronic acid, the medium composition comprising arginine and uridine, and a method for producing hyaluronic acid using same. The medium composition for a microorganism producing hyaluronic acid, according to an aspect, can be used to produce hyaluronic acid with increased efficiency.